Critical COVID-19 cases may stem from an unexpected genetic vulnerability in how cells detect viral invasion. While most people mount robust interferon responses that limit SARS-CoV-2 replication, some individuals appear genetically predisposed to immune failure at the cellular level.
Researchers identified rare deleterious variants in POLR3A and POLR3C genes among patients with critical COVID-19. These genes encode RNA polymerase III, which functions as a cytosolic DNA sensor triggering type I interferon production when mitochondrial DNA leaks into the cytoplasm during viral infection. The defective polymerase fails to properly detect this cellular distress signal, leaving pulmonary epithelial cells unable to mount adequate antiviral responses.
This finding illuminates a previously unrecognized layer of COVID-19 susceptibility beyond age and comorbidities. RNA polymerase III represents a critical early-warning system that alerts the immune system to viral presence by sensing mitochondrial DNA displacement. When this sensor malfunctions due to genetic variants, the downstream interferon cascade never properly activates, allowing unchecked viral replication in lung tissue.
The discovery adds RNA polymerase III to the growing list of innate immunity genes linked to severe COVID-19 outcomes, joining previously identified variants in interferon pathway components. However, this represents a more upstream defect in viral sensing rather than interferon signaling itself. For clinical practice, genetic screening for POLR3A and POLR3C variants could potentially identify high-risk individuals requiring enhanced protection or early intervention. The mechanistic insights also suggest therapeutic targets for boosting interferon responses in genetically susceptible patients, though translating this knowledge into treatments remains years away.